Floatz logo

LEVODOPA

Cardiovascular Event

GlaxoSmithKlineSmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

60 Active assets in the Cardiovascular Event cohort.

Asset / SponsorPhaseRating
Acetylsalicylic Acid
AstraZeneca
Phase 4BBB
Liraglutide
University of Sao Paulo General Hospital
Phase 4BBB
Lipitor
Duke University
Phase 4BBB
Rosuvastatin
Nanjing First Hospital, Nanjing Medical University
Phase 4BBB
SIMVASTATIN
McMaster University
Phase 4BBB

View all 50 →

Same molecule, other indications

LEVODOPA is also rated in:

drug-induced dyskinesiaDormant
A
Indicative ·
80 / 100
View asset →
Parkinson diseaseDormant
BBB
Indicative ·
75 / 100
View asset →
movement disorderDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →